Abstracts

INTERIM ANALYSIS OF A PHASE I STUDY OF PRTX007: SAFETY, PK, AND PD RESPONSE

PRTX007 is a prodrug of PRX034, a novel TLR7 agonist, for treatment of respiratory viral diseases including SARS-CoV-2. PRX034 activates plasmacytoid dendritic cells to preferentially synthesize poly sub-type interferons while minimizing NF??-mediated proinflammatory factors. Pre-clinical studies have demonstrated decoupling of these two normally linked processes in human PBMCs in vitro and in cynomolgus monkeys in…

CETYLPYRIDINIUM CHLORIDE MOUTHWASHES TO REDUCE THE SHEDDING OF VIABLE SARS-CoV-2

SARS-CoV-2 is spread via airborne transmission. Mouthwashes containing virucidal compounds can help reduce viral spread. Here we show that cetylpyridinium chloride (CPC), a quaternary ammonium present in many oral mouthwashes, reduces SARS-CoV-2 infectivity by disrupting viral membranes both in vitro and in vivo. We tested the capacity of CPC-containing mouthwashes to inhibit SARS-CoV-2 entry into…

TENOFOVIR URINE POINT-OF-CARE TEST PREDICTS VIREMIA AND DRUG RESISTANCE DURING ART

Recommended first-line ART in low- and middle-income countries (LMIC) is dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) or emtricitabine (FTC) accompanied by annual HIV viral load (VL) testing for treatment monitoring. Viremia during DTG-based ART is often due to suboptimal adherence in the absence of resistance. We hypothesize that qualitative point-of-care (POC) detection…

NOVEL PHASE II TRIAL DESIGN WITH STRATIFIED MEDICINE PRINCIPLES FOR TREATMENT OF TB

A5349/S31 showed a 4-month rifapentine-moxifloxacin-based regimen had comparable efficacy to the standard 6-month regimen for the treatment of drug-susceptible tuberculosis (TB). Despite this, we identified subgroups of A5349/S31 participants assigned to the 4-month regimen who were either low-risk and likely did not require 4 months of treatment, or high-risk and experienced unacceptably high relapse rates…

PHASE-2 STUDY OF SAB-185, A POLYCLONAL ANTIBODY TREATMENT FOR COVID-19 IN ACTIV-2

The discovery and development of SARS-CoV-2 therapies remains a priority. SAB-185 is a Transchromosomic, bovine-derived, fully human polyclonal immunoglobulin product for SARS-CoV-2 being studied in ACTIV-2, randomized controlled platform trial evaluating the safety and efficacy of investigational agents for non-hospitalized adults with mild-moderate COVID-19 This phase 2 trial was a superiority comparison of SAB-185 vs.…

MODELING REMDESIVIR ANTIVIRAL EFFICACY IN COVID-19 HOSPITALIZED PATIENTS

Despite several clinical studies, the antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. We analyzed nasopharyngeal normalized viral loads collected in the 29 days following randomization from 665 hospitalized patients included in the DisCoVeRy trial, allocated to either standard of care (SoC, N=329) or SoC + remdesivir for 10 days (N=336). We used…

SAFETY OF REMDESIVIR VS PLACEBO IN NONHOSPITALIZED PATIENTS WITH COVID-19

Remdesivir (RDV), a potent nucleotide inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase, effectively reduces COVID-19 related hospitalization in outpatients at high risk for progression to severe disease. However, limited data exist on the safety profile of RDV in this population. We conducted a phase 3 placebo-controlled study evaluating a 3-day regimen of RDV in non-hospitalized…

A RANDOMIZED CONTROLLED TRIAL OF CAMOSTAT IN OUTPATIENTS WITH COVID-19

Camostat, an oral protease inhibitor, blocks entry and replication of SARS-CoV-1 and SARS-CoV-2 in vitro. It is approved for therapy of recurrent pancreatitis in several countries. Camostat has an excellent safety profile and repurposing for COVID-19 treatment was proposed. We conducted a phase 2 randomized, placebo-controlled trial of camostat in adult outpatients with confirmed COVID-19…